Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.6K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

597
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
597

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cell-free mitochondrial DNA and microRNA-137 for early diagnosis of preeclampsia.

Frontiers in cardiovascular medicine·2026
Same author

Perspective on Epicardial Adipose tissue.

European journal of internal medicine·2025
Same author

Mortality Across the Pre- and Post-Heart Transplant Continuum for Patients With Severe Obesity.

JACC. Heart failure·2025
Same author

Clinical correlates of perivascular adipose tissue in coronary artery disease and obesity.

Frontiers in physiology·2025
Same author

Sex-Specific Disparities in the Female Vs Male Patient Population in Left Ventricular Assist Device Use.

CJC open·2025
Same author

Skeletal Muscle Mass Loss and Glucagon-Like Peptide-1 Receptor Agonists: Are Older Patients at Risk?

Annals of internal medicine·2025
Same journal

Prophylactic ACE inhibition in anthracycline-induced cardiotoxicity: signal, context, and clinical uncertainty.

Journal of cardiovascular pharmacology·2026
Same journal

Imipramine Can Block Human Cardiac H1-Histamine Receptors.

Journal of cardiovascular pharmacology·2026
Same journal

Ivabradine in the Treatment of POTS Before and After COVID-19 Pandemic: A Systematic Review and Meta-Analysis.

Journal of cardiovascular pharmacology·2026
Same journal

Mineralocorticoid receptor antagonists in managing hypertension: a link with diurnal patterns of blood pressure.

Journal of cardiovascular pharmacology·2026
Same journal

The Cardiac Sarcomere: From development of heritable cardiomyopathies to gene and precision therapies.

Journal of cardiovascular pharmacology·2026
Same journal

Efficacy and Safety of Lorundrostat for Uncontrolled and Treatment-resistant Hypertension: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Journal of cardiovascular pharmacology·2026
See all related articles

Related Experiment Video

Updated: Apr 30, 2026

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

2.5K

Toward safe inotropic therapy.

Indranee N Rajapreyar1, Pierre V Ennezat, Thierry H Le Jemtel

  • 1*Division of Cardiology, University of Texas, Houston, TX; †Division of Cardiology, Centre Hospitalier Universitaire de Grenoble, France; and ‡Department of Cardiology, Tulane University Medical School, New Orleans, LA.

Journal of Cardiovascular Pharmacology
|May 3, 2014
PubMed
Summary
This summary is machine-generated.

Current positive inotropic agents worsen outcomes. Novel agents should avoid increasing intracellular calcium and oxygen demand, potentially improving heart failure treatment.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.2K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.9K

Related Experiment Videos

Last Updated: Apr 30, 2026

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

2.5K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.2K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.9K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Current positive inotropic agents are linked to poor clinical outcomes.
  • These agents can cause adverse effects like arrhythmias, myocardial ischemia, and energy depletion.
  • Existing therapies increase intracellular calcium and myocardial oxygen demand.

Purpose of the Study:

  • To evaluate the limitations of current positive inotropic agents.
  • To identify characteristics of novel inotropic agents for improved safety and efficacy.
  • To explore alternative mechanisms for enhancing left ventricular systolic performance.

Main Methods:

  • Review of existing literature on positive inotropic agents.
  • Analysis of the mechanisms of action and clinical outcomes associated with these agents.
  • Theoretical evaluation of novel therapeutic strategies, such as myosin activators.

Main Results:

  • Positive inotropic agents increase intracellular calcium and myocardial oxygen demand, leading to adverse effects.
  • Myosin activators improve left ventricular systolic performance by prolonging ejection time without increasing contractility.
  • This mechanism avoids detrimental effects on diastolic intracellular calcium, oxygen demand, and energy expenditure.

Conclusions:

  • Novel inotropic agents must avoid increasing intracellular calcium and myocardial oxygen consumption for safer use.
  • Myosin activators represent a promising therapeutic approach for heart failure.
  • Targeting left ventricular ejection time offers a potential strategy for improving cardiac function without adverse effects.